Related Experiment Video
Updated: Jun 21, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Chalcone based aryloxypropanolamines as potential antihyperglycemic agents.
Poonam Shukla1, Amar Bahadur Singh, Arvind Kumar Srivastava
1Central Drug Research Institute, Lucknow, India.
Bioorganic & Medicinal Chemistry Letters
|November 11, 2006
Summary
New chalcone-based aryloxypropanolamines show promising antihyperglycemic effects in rat models. The most potent compound demonstrated significant glucose lowering, indicating potential for diabetes treatment development.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Diabetes mellitus is a global health concern requiring novel therapeutic agents.
- Chalcone derivatives are known for diverse biological activities, including potential antihyperglycemic properties.
Purpose of the Study:
- To synthesize and evaluate a series of chalcone-based aryloxypropanolamines for antihyperglycemic activity.
- To identify structure-activity relationships (SAR) to guide further drug design.
Main Methods:
- Synthesis of novel chalcone-based aryloxypropanolamine compounds.
- In vivo evaluation of antihyperglycemic activity using streptozotocin (STZ)-induced and sterile lipid-induced (SLM) rat models.
Main Results:
- Most synthesized compounds displayed moderate to good antihyperglycemic activity.
- Activities ranged from 6.5% to 31.1% in SLM models and 8.3% to 22.6% in STZ models.
- Compound 5g was the most potent, showing 26.7% glucose lowering in SLM and 22.6% in STZ models.
Conclusions:
- Chalcone-based aryloxypropanolamines represent a promising class of compounds for antihyperglycemic drug discovery.
- A clear structure-activity relationship was established, particularly concerning the amine group in ring B.
More Related Videos
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...